Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

A minimal clinically important difference for the sleep inertia visual analog scale in idiopathic hypersomnia.

A minimal clinically important difference for the sleep inertia visual analog scale in idiopathic hypersomnia. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine Bogan, R. K., Fuller, D. S., Whalen, M., Casstevens, C., Schneider, L. D. 2025

Abstract

STUDY OBJECTIVES: Measurement tools for sleep inertia, a common and important idiopathic hypersomnia symptom, are limited. For individuals with idiopathic hypersomnia, this post hoc analysis proposes a minimal clinically important difference (MCID) for the Sleep Inertia Visual Analog Scale (SI-VAS), which assesses difficulty waking up.METHODS: Data from the pivotal phase 3, double-blind, placebo-controlled, randomized withdrawal study (NCT03533114) of low-sodium oxybate in adults with idiopathic hypersomnia were used to estimate an SI-VAS MCID anchored to the Patient Global Impression of Change (PGIc), Idiopathic Hypersomnia Severity Scale (IHSS), and Functional Outcomes of Sleep Questionnaire (FOSQ-10).RESULTS: Of 109 participants included, majority female (69.7%) and White (81.7%), most were at least moderately ill (95%) per baseline Clinical Global Impression of Severity. SI-VAS score changes were strongly associated with PGIc levels (Kruskal-Wallis test statistic, 110.2; P<0.0001). Estimated mean (SE) difference in SI-VAS scores between consecutive PGIc levels was 10.9 (0.8) mm, suggesting an MCID estimate of 10-12 mm. SI-VAS was also highly correlated with IHSS (Pearson r, 0.79; P<0.0001) and FOSQ-10 (Pearson r, -0.74; P<0.0001). Mean (SE) SI-VAS change per 4-unit IHSS change (MCID) was 6.0 (0.3) mm and per 2-unit FOSQ-10 change (cutpoint) was 8.5 (0.5) mm.CONCLUSIONS: Establishing an MCID strengthens the SI-VAS value, adds context for findings related to sleep inertia in individuals with idiopathic hypersomnia from the phase 3 study, and aids clinicians in identifying clinically meaningful changes in sleep inertia to improve patient outcomes.CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Identifier: NCT03533114; Name: A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension; URL: https://www.clinicaltrials.gov/study/NCT03533114.

View details for DOI 10.5664/jcsm.11662

View details for PubMedID 40135693